Christopher Sarko
Research Subjects
Christopher Sarko has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Colin Osborne
Novartis Institute for Tropical Diseases, Emeryville, CA, USA
2 shared publications - Suresh Bangalore Lakshminarayana
Global Health, Biomedical Research , Novartis, Emeryville, California
2 shared publications - Thierry Tidiane Diagana
Novartis Institute for Tropical Diseases, Emeryville, CA, USA
2 shared publications - Yen-Liang Chen
Novartis Institute for Tropical Diseases, Singapore
2 shared publications - Amanda Fortes Francisco
Department of Infection Biology, London School of Hygiene and Tropical Medicine, UK
1 shared publication - Andreas Daniel Schenk
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
1 shared publication
Latest Publications
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.
- 18 November 1997
- Published by Wiley in ChemInform
- Vol. 28 (47)
ChemInform Abstract: Efficient Stereoselective Synthesis of the Epoxyacid Fragment of the Azinomycins.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
- 18 November 1997
- Published by Wiley in ChemInform
- Vol. 28 (47)
ChemInform Abstract: Efficient Stereoselective Synthesis of the Epoxyacid Fragment of the Azinomycins.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.